CLAIMS

1. Amino-terminally truncated RANTES, lacking NH₂-terminal amino acids corresponding to amino acid residues 1, 1-2, 1-3 or 1-4 of the naturally-occurring RANTES and having chemokine antagonistic activity.

5

10

20

- 2. Amino-terminally truncated RANTES according to claim 1, lacking NH₂-terminal amino acids corresponding to amino acid residues 1-2 of the naturally-occurring RANTES and having a chemokine antagonistic activity
- 3. Amino-terminally truncated RANTES according to claim 1, having the amino acid sequence of SEQ ID NO: 2.
- 4. Amino-terminally truncated RANTES, according to one or more of the preceding claims, in a glycosylated form.
 - 5. DNA molecules comprising the DNA sequences soding for the amino-terminally truncated RANTES of the invention according to one or more of the preceding claims, including nucleotide sequences substantially the same.
 - 6. An expression vector which comprises the DNA molecule of any claim 5.
 - 7. A host cell comprising the expression vector of claim 6.
- 8. A recombinant process for preparing any of the proteins from claim 1 to 4, comprising culturing in an appropriate culture medium the cells of claim 7.
 - 9. A protein according to any of the claims from 1 to 4 for use as medicament.

- 10. Use of a protein according to any of the claims from 1 to 4, in the manufacture of a medicament for the therapy and/or diagnosis of diseases, in which an antagonistic activity of the chemokine effects is required.
- 5 11.Use according to claim 10, in the manufacture of a medicament for the treatment of inflammatory diseases, HIV-infection, angiogenisis- and hematopoiesis-related diseases, and tumors.
- 12.A pharmaceutical composition comprising the protein according to any of the claims
 from 1 to 4 together with one or more pharmaceutically acceptable carriers and/or
 excipients.
 - 13.Use of CD26/DPP IV in the therapy and/or diagnosis of the diseases, in which an antagonistic activity of the chemokine effects is required.
 - 14.Use according to claim 13, for the treatment of inflammatory, immune and infectious diseases.

15